Association between CA 15‑3 and progression of interstitial lung disease in a case of coexisting systemic sclerosis and recurrent breast cancer: A case report-Reference-Cited by-同舟云学术

Association between CA 15‑3 and progression of interstitial lung disease in a case of coexisting systemic sclerosis and recurrent breast cancer: A case report

Published:2022-08-08 Issue:4 Volume:17 Page:
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:
Short-container-title:Mol Clin Oncol

Author:

Ohara Masahiro¹,Koi Yumiko¹,Sasada Tatsunari¹,Kajitani Keiko¹,Mizuno Seishi²,Takata Ai²,Okamoto Atsuko²,Nagata Ikuko²,Sumita Mie²,Imachi Kaita²,Watanabe Mayumi²,Daimaru Yutaka²,Yoshida Yusuke³

Affiliation:

1. Department of Breast Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738‑8503, Japan

2. Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738‑8503, Japan

3. Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734‑8553, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference70 articles.

1. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers;Sturgeon;Clin Chem,2008

2. Biochemical markers in breast cancer: Which ones are clinically useful?;Duffy;Clin Biochem,2001

3. Predictive markers in breast and other cancers: A review;Duffy;Clin Chem,2005

4. Biomarkers in breast cancer: Where Are we and where are we going?;Duffy;Adv Clin Chem,2015

5. CA 15-3: Uses and limitation as a biomarker for breast cancer;Duffy;Clin Chim Acta,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paclitaxel/pertuzumab/trastuzumab;Reactions Weekly;2022-10-15